Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers-Reference-Cited by-同舟云学术

Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers

Published:2016-01-04 Issue:9 Volume:55 Page:1556-1565
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Kearsley-Fleet Lianne,Davies Rebecca,Baildam Eileen,Beresford Michael W.,Foster Helen E.,Southwood Taunton R.,Thomson Wendy,Hyrich Kimme L.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Reference38 articles.

1. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register;Symmons;J Rheumatol,1996

2. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001;Petty;J Rheumatol,2004

3. European Medicines Agency/Committee for Medicinal Products for Human Use. Enbrel. Summary of opinion (post authorisation). 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000262/human_med_000764.jsp&mid=WC0b01ac058001d124 (5 May 2015, date last accessed).

4. National Institute for Health and Care Excellence. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. 2002. https://www.nice.org.uk/guidance/ta35 (1 December 2015, date last accessed).

5. National Institute for Health and Care Excellence. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. 2011. https://www.nice.org.uk/Guidance/TA238 (30 November 2015, date last accessed).

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Greater DMARD use, improved clinical but not patient-reported outcomes in juvenile idiopathic arthritis: what are we missing?;Rheumatology;2024-01-04

2. Refractory inflammatory arthritis definition and model generated through patient and multi-disciplinary professional modified Delphi process;PLOS ONE;2023-08-09

3. Biological Agent Switching in Patients With Juvenile Idiopathic Arthritis;JCR: Journal of Clinical Rheumatology;2023-04-16

4. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis;Rheumatology;2022-09-15

5. Research progress in drug therapy of juvenile idiopathic arthritis;World Journal of Pediatrics;2022-04-01